A Study of CHML Treatments For Patients With Advanced Hepatic Malignancies
(Brief)

Purpose

The purpose of the study is to evaluate the survival, efficacy, toxicity, and quality of life provided from Cytotropic Heterogeneous Molecular Lipids (CHML) to patients with advanced hepatic malignancies in whom previous therapies have failed.

Eligibility Criteria

Inclusion Criteria:

- Ages eligible for study: 18 years and above; genders eligible for study: both
- Histologically or cytologically documented hepatic malignancy
- Life expectancy of at least 12 weeks
- Tumor size measurements using CT or MRI according to WHO recommendations
- Advanced hepatic malignancies in whom previous therapy has failed
- Adequate major organ function at 0-1 grade according to WHO toxicity guidelines
- Karnofsky PS $\geq 60$

Exclusion Criteria:

- Advanced hepatic malignancy with metastatic disease
- Jaundice, ascites, portal thrombosis, or arteriovenous fistula causing from hepatic malignancy
- Proper hepatic artery embolism
- Terminal decompensated hepatocirrhosis
- Cachexia or asthenia universalis
- Disseminated intravascular coagulation (DIC)
- Schematic heart disease
- Uncontrolled diabetes
- Uncontrolled inflammation
- Known history of human immunodeficiency virus (HIV)
- Previous serious hypersensitivity reaction to lipids, or Iodine

Trial Contact Information

Trial Lead Organizations/Sponsors

Glory Ltd, USA